Last reviewed · How we verify
Cardinacillin (carindacillin)
Carindacillin, marketed by Pfizer, is a bacterial urinary infection treatment currently generating revenue in the market with a key composition patent expiring in 2028. Its mechanism of action, inhibiting bacterial transpeptidase, provides a targeted approach to disrupting bacterial cell wall synthesis, distinguishing it within the same class of antibiotics such as ampicillin and amoxicillin. The primary risk to Carindacillin's market position is the presence of multiple off-patent competitors, including ampicillin and azlocillin, which may limit its market share and pricing power.
At a glance
| Generic name | carindacillin |
|---|---|
| Sponsor | Pfizer |
| Drug class | Penicillin-class Antibacterial |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1972 |
Approved indications
- Bacterial urinary infection
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cardinacillin CI brief — competitive landscape report
- Cardinacillin updates RSS · CI watch RSS
- Pfizer portfolio CI